Although immunotherapy would be a major shift in treatments for gastric and esophageal cancers, 3 studies have found benefits for these patient populations, who currently have poor survival rates. Results of these studies were presented during the ESMO Virtual Congress 2020.
https://www.pharmacytimes.com/conferences/esmo-2020/studies-find-immunotherapy-beneficial-to-gastric-esophageal-cancers